Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

TOKYO and CAMBRIDGE, Mass., Oct 31, 2024 – (JCN Newswire) – Eisai Co., Ltd. and Biogen Inc.  announced today that the latest findings for lecanemab-irmb (U.S. brand name: LEQEMBI®), an anti-amyloid beta (Aβ) protofibril* antibody for the treatment of early Alzheimer’s disease (AD), were presented at the Clinical Trials for Alzheimer’s Disease Conference (CTAD…
Read More